Aprea Therapeutics Inc’s recent filing unveils that its President/CEO Gilad Oren acquired Company’s shares for reported $10110.0 on Apr 03 ’25. In the deal valued at $1.84 per share,5,500 shares were bought. As a result of this transaction, Gilad Oren now holds 345,620 shares worth roughly $0.62 million.
Then, Duey Marc sold 6,462 shares, generating $29,583 in total proceeds. Upon selling the shares at $4.58, the Director now owns 233,651 shares.
Before that, Gilad Oren bought 500 shares. Aprea Therapeutics Inc shares valued at $1,958 were divested by the President/CEO at a price of $3.92 per share. As a result of the transaction, Gilad Oren now holds 333,395 shares, worth roughly $0.6 million.
Robert W. Baird downgraded its Aprea Therapeutics Inc [APRE] rating to a Neutral from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. H.C. Wainwright started covering the stock on June 22, 2020. It rated APRE as “a Neutral”.
Price Performance Review of APRE
On Tuesday, Aprea Therapeutics Inc [NASDAQ:APRE] saw its stock jump 5.29% to $1.79. Over the last five days, the stock has gained 1.70%. Aprea Therapeutics Inc shares have fallen nearly -51.62% since the year began. Nevertheless, the stocks have fallen -45.59% over the past one year.
How much short interest is there in Aprea Therapeutics Inc?
A steep rise in short interest was recorded in Aprea Therapeutics Inc stocks on 2025-07-15, dropping by 9720.0 shares to a total of 63189.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 72909.0 shares. There was a decline of -15.38%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 21, 2020 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $45 price target.
